dc.contributor.advisor | Cibula, David | |
dc.creator | Fait, Tomáš | |
dc.date.accessioned | 2018-09-18T10:01:49Z | |
dc.date.available | 2018-09-18T10:01:49Z | |
dc.date.issued | 2008 | |
dc.identifier.uri | http://hdl.handle.net/20.500.11956/14317 | |
dc.description.abstract | The aim of project was to evaluate which of aplication forms of estrogen replacement therapy (in daily doses 2 mg estradiol orally or 0,05 mg estradiol transderma) is better for postmenopausal women from the view of cardiovascular risk. Oral aplication was conected with favourable elevation of HDL-cholesterol level and lowering of prothrombin activator inhibitor (PAI-1). On the other side there were elevation of tigylcerides and high selective C-reactive protein (hs CRP) and lowering of tissue factor pathway inhibitor (TFPI). Transdermal therapy was conjoined with elevation of HDL-cholesterol. Other markers were not influenced by this aplication form. Transdermal estrogen replacement therapy is more favourable than oral estrogen replacement therapy from the view of cardiovascular risks. The choice of hormone replacement therapy must be strongly individual. The knowledge of level lipids and other factors of cardivascular risk, could be helpfull during choice of aplication form, dose and contents of hormone replacement therapy. | en_US |
dc.language | Čeština | cs_CZ |
dc.language.iso | cs_CZ | |
dc.publisher | Univerzita Karlova, 1. lékařská fakulta | cs_CZ |
dc.title | Metabolické aspekty hormonální substituční terapie u postmenopauzálních žen | cs_CZ |
dc.type | dizertační práce | cs_CZ |
dcterms.created | 2008 | |
dcterms.dateAccepted | 2008-02-06 | |
dc.description.department | Department of Gynaecology and Obstetrics First Faculty of Medicine and General University Hospital | en_US |
dc.description.department | Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze | cs_CZ |
dc.description.faculty | First Faculty of Medicine | en_US |
dc.description.faculty | 1. lékařská fakulta | cs_CZ |
dc.identifier.repId | 70024 | |
dc.title.translated | Metabolic aspects of the hormone replacement therapy in menopause | en_US |
dc.contributor.referee | Češka, Richard | |
dc.contributor.referee | Hořejší, Jan | |
dc.identifier.aleph | 001482524 | |
thesis.degree.name | Ph.D. | |
thesis.degree.level | doktorské | cs_CZ |
thesis.degree.discipline | - | cs_CZ |
thesis.degree.discipline | - | en_US |
thesis.degree.program | Experimental Surgery | en_US |
thesis.degree.program | Experimentální chirurgie | cs_CZ |
uk.thesis.type | dizertační práce | cs_CZ |
uk.taxonomy.organization-cs | 1. lékařská fakulta::Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze | cs_CZ |
uk.taxonomy.organization-en | First Faculty of Medicine::Department of Gynaecology and Obstetrics First Faculty of Medicine and General University Hospital | en_US |
uk.faculty-name.cs | 1. lékařská fakulta | cs_CZ |
uk.faculty-name.en | First Faculty of Medicine | en_US |
uk.faculty-abbr.cs | 1.LF | cs_CZ |
uk.degree-discipline.cs | - | cs_CZ |
uk.degree-discipline.en | - | en_US |
uk.degree-program.cs | Experimentální chirurgie | cs_CZ |
uk.degree-program.en | Experimental Surgery | en_US |
thesis.grade.cs | Prospěl/a | cs_CZ |
thesis.grade.en | Pass | en_US |
uk.abstract.en | The aim of project was to evaluate which of aplication forms of estrogen replacement therapy (in daily doses 2 mg estradiol orally or 0,05 mg estradiol transderma) is better for postmenopausal women from the view of cardiovascular risk. Oral aplication was conected with favourable elevation of HDL-cholesterol level and lowering of prothrombin activator inhibitor (PAI-1). On the other side there were elevation of tigylcerides and high selective C-reactive protein (hs CRP) and lowering of tissue factor pathway inhibitor (TFPI). Transdermal therapy was conjoined with elevation of HDL-cholesterol. Other markers were not influenced by this aplication form. Transdermal estrogen replacement therapy is more favourable than oral estrogen replacement therapy from the view of cardiovascular risks. The choice of hormone replacement therapy must be strongly individual. The knowledge of level lipids and other factors of cardivascular risk, could be helpfull during choice of aplication form, dose and contents of hormone replacement therapy. | en_US |
uk.file-availability | V | |
uk.publication.place | Praha | cs_CZ |
uk.grantor | Univerzita Karlova, 1. lékařská fakulta, Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze | cs_CZ |
thesis.grade.code | P | |
dc.identifier.lisID | 990014825240106986 | |